Novel cell therapy for anemia of CKD

治疗 CKD 贫血的新型细胞疗法

• 批准号: 8305209
• 负责人: MATTHEW H WILSON
• 金额: $ 34.04万
• 依托单位: BAYLOR COLLEGE OF MEDICINE
• 依托单位国家: 美国
• 财政年份: 2012
• 资助国家: 美国
• 起止时间: 2012-07-01 至 2017-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8305209
• 关键词: Ablation; Adverse effects; Affect; Alternative Therapies; Anemia; Animals; Antigens; Bolus Infusion; Cell Therapy; Cells; Chronic; Chronic Kidney Failure; Cicatrix; Clinical Research; Deep Vein Thrombosis; Dose; Effectiveness; Erythropoietin; Experimental Designs; Fibroblasts; Frequencies; Gene Activation; Gene Expression; Gene Transfer; Gene-Modified; Genes; Genetic; Genomics; Hematocrit procedure; Hormones; Human; Human Herpesvirus 4; Immunophenotyping; In Vitro; Injection of therapeutic agent; Latent Virus; Life; Maintenance; Measures; Mediating; Modeling; Modification; Mus; Myocardial Infarction; Patients; Physiological; Population; Property; Recombinant Erythropoietin; Red Blood Cell Count; Regulation; Risk; Safety; Signal Pathway; Site; Specificity; Stroke; System; T-Lymphocyte; Testing; Tetracyclines; Thrombosis; Toxic effect; Transgenes; Vaccination; Viral Antigens; Virus; Wild Type Mouse; analog; genotoxicity; human disease; in vivo; innovation; mouse model; novel; patient population; pre-clinical; preclinical evaluation; response; suicide gene; therapeutic protein

DESCRIPTION (provided by applicant): Chronic kidney disease (CKD) affects an estimated 7% of the US population and results in scarring and loss of peritubular fibroblasts which produce erythropoietin (EPO). EPO-deficient anemia of CKD is currently treated with recombinant EPO analog injections that have recently been associated with undesired side effects such as increased risk of stroke, heart attacks, and deep vein thrombosis which may preclude further use of this therapy. Although the mechanisms of these side effects are unclear, it is clear that bolus dosing of EPO analogs either weekly or monthly does not recapitulate the physiologic regulation of this important hormone and bolus dosing may alter EPO signaling pathways. Thus, there is a critical need to develop alternative therapies for anemia of CKD. Herein we describe an innovative experimental design using non-viral transposon-mediated gene transfer to develop a new strategy for therapy of anemia of CKD. Genetically modified T lymphocytes whose specificity is directed to persistent (latent) viruses such as Epstein-Barr virus (EBV) survive long-term (>8 years) in stable numbers in vivo due to chronic viral antigen stimulation. Moreover, preclinical and recent clinical studies have shown T cells can be readily induced to apoptose by activation of a co-transferred suicide gene, providing an additional layer of safety and control. We therefore hypothesize that virus specific T cells genetically modified to inducibly express EPO and a separately inducible suicide gene represent an ideal candidate cell population for sustained and safe treatment of anemia of CKD. In specific aim 1, we propose to modify virus specific murine T cells to inducibly express EPO and a suicide gene and we will infuse them into wild type and CKD mice to measure their effectiveness in regulating hematocrit levels in vivo. Specific aim 2 focuses on extending these genetic modifications to human T cells and testing them in vitro for their ability to be propagated long-term via chronic viral antigen stimulation, as well as inducibly express EPO and undergo selectively induced cell ablation if needed. In specific aim 3, we will evaluate the functionality of genetically modified human T cells from patients with CKD and determine the frequency of EBV-specific T cells and their response to EBV antigen in the presence and absence of transgenically expressed EPO ex vivo. PUBLIC HEALTH RELEVANCE: This project is focused on developing an efficient, safe, and novel cell therapy for anemia of chronic kidney disease. The proposed strategy could also be used for therapy for a variety of other human diseases.

描述（由申请人提供）：慢性肾脏疾病（CKD）影响约7%的美国人口，并导致瘢痕形成和产生促红细胞生成素（EPO）的肾小管周围成纤维细胞丧失。EPO缺乏性贫血的CKD目前用重组EPO类似物注射治疗，其最近与不期望的副作用相关，如中风、心脏病发作和深静脉血栓形成的风险增加，这可能妨碍进一步使用该疗法。虽然这些副作用的机制尚不清楚，但很明显，每周或每月推注EPO类似物并不能概括这种重要激素的生理调节，推注给药可能会改变EPO信号传导途径。因此，迫切需要开发CKD贫血的替代疗法。在此，我们描述了一个创新的实验设计，使用非病毒转座子介导的基因转移，以开发一个新的策略，治疗慢性肾脏病贫血。由于慢性病毒抗原刺激，其特异性针对持久性（潜伏性）病毒如EB病毒（EBV）的遗传修饰的T淋巴细胞在体内以稳定的数量长期（>8年）存活。此外，临床前和最近的临床研究表明，通过激活共转移的自杀基因，T细胞可以容易地被诱导为果糖，从而提供了额外的安全和控制层。因此，我们假设病毒特异性T细胞经过基因修饰， 表达EPO和单独诱导的自杀基因代表了用于持续和安全治疗CKD贫血的理想候选细胞群。在具体目标1中，我们提出修饰病毒特异性鼠T细胞以诱导表达EPO和自杀基因，并且我们将它们注入野生型和CKD小鼠中以测量它们在体内调节血细胞比容水平的有效性。具体目标2的重点是将这些遗传修饰扩展到人类T细胞，并在体外测试它们通过慢性病毒抗原刺激长期繁殖的能力，以及诱导表达EPO和在需要时进行选择性诱导细胞消融的能力。在具体目标3中，我们将评估遗传修饰的人T细胞的功能性， 并测定EBV特异性T细胞的频率及其在转基因表达的EPO存在和不存在的情况下离体对EBV抗原的应答。 公共卫生相关性：该项目的重点是开发一种有效，安全和新颖的细胞疗法治疗慢性肾脏疾病贫血。所提出的策略也可用于治疗各种其他人类疾病。